ESMO 2026: When Immune Organs Are Removed: The Impact on Cancer Risk
In this MEDtalk from ESMO 2026, Ida Maria Hemdorf Eriksen, MD, PhD student, Department of Molecular Medicine, Aarhus University Hospital, Denmark, explores the potential consequences of removing immune-related organs for immune surveillance and subsequent cancer risk. She examines whether organ removal may compromise the body’s ability to detect and eliminate cancer cells, potentially allowing them to evade immune control and develop into clinically apparent cancer. Focusing on the tonsils, spleen, and thymus, she presents findings on the relationship between organ removal and subsequent cancer risk.







